摘要
目的:应用抗血管生成药物酞咪哌啶酮进行乳腺癌肝转移患者的维持治疗,探讨其疗效以及安全性。方法:完成一线有效化疗的乳腺癌肝转移患者32例,随机分为维持治疗组和对照组。维持治疗组给予酞咪哌啶酮口服100mg/d,对照组定期随访观察。比较两组患者无进展生存期(PFS)、转移后中位生存期(MSR),观察近期临床疗效、患者生活质量以及不良反应发生情况。结果:与对照组比较,维持治疗组PFS延长(P<0.05)、MSR延长(P>0.05),总有效率高于对照组(P<0.05)。Karnofsky评分改善率高于对照组(P<0.05),未出现严重不良反应。结论:一线有效治疗后给予酞咪哌啶酮维持治疗,可以提高临床治疗效果、延长乳腺癌肝转移患者的无进展生存期,毒性低、安全性好,能够改善患者的生活质量,为乳腺癌肝转移维持治疗提供新的治疗思路。
Objective ：To explore the efficacy and safety of thalidomide which is an anti - angiogenesis agent in the lnaintenance treatment of breast cancer patients with liver metastases. Methods：Thirty - two patients,who have been treated by efficacious chelnotherapy treatment,were divided into thalidomide maintenance therapy group and control group according to the different treatment lnethods. Patients in the experimental group （n=16） were given thalido- mide 100mg/d for at least four months, in the control group （n=16）, observation was lille regularly. The MRS, PFS,short - terln clinical efficacy, side effects and security in two groups were observed and compared. Results： Coin- pared with the control group,in the maintenance therapy group PFS （P 〈 0.05 ） and MRS （P 〉 0.05） were longer, in the maintenance therapy group,the RR was significantly higher than the control group （P 〈 0.05 ）. Karnofsky score improved rate of maintenance therapy group was higher than the control group （P 〈 0.05）. There was no significant side effect which threatened the life. Conclusion：in the maintenance treatment following efficacious chemotherapy, thulidomide could prolong PFS,improve clinical effect and quality of life. Thalidomide provided a well - tolerated and active therapy regimen for advanced breast cancer with liver metastasis.
出处
《现代肿瘤医学》
CAS
2014年第3期545-548,共4页
Journal of Modern Oncology
基金
陕西省国际合作重点项目(编号:2013KW-32-01)
关键词
酞咪哌啶酮
乳腺癌
肝转移
抗血管生成
维持治疗
thalidomide
breast cancer
liver metastasis
anti - angiogenesis
maintenance therapy
